Perspective Therapeutics, Inc. (CATX)

Over the past six months, Perspective Therapeutics' stock (CATX) has experienced significant price movements and been impacted by several events. The stock price has increased by 6.43% over the last six months. As of April 10, 2026, the share price was $4.46, representing a 128.72% increase over the past year. In the past month, the stock decreased by 16.45% or 17.57%. On February 18, 2026, CATX's 50-day moving average crossed bullishly above its 200-day moving average. The company announced its participation in upcoming investor conferences, including the Piper Sandler Spring Biopharma Symposium on April 16, 2026. On March 17, 2026, Perspective Therapeutics announced the acceptance of VMT-α-NET data for presentation at the AACR Annual Meeting 2026. The company provided business highlights and reported full-year 2025 results on March 16, 2026, which included an increase in R&D investment, an extended cash runway into late 2027, and positive tolerability and progression-free rates for VMT-α-NET. The net loss for the year ended December 31, 2025, was $103.1 million. On February 17, 2026, the company announced it would provide business highlights and report full-year 2025 financial results. In February 2026, the company completed an underwritten offering, generating approximately $164 million in net proceeds, which is expected to fund operations into late 2027. In October 2025, the company reported positive interim data from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for neuroendocrine tumors, showing promising efficacy and a favorable safety profile. Perspective Therapeutics is expected to release its next earnings report on May 19, 2026.

Based on the available information, there is no explicit indication of demand seasonality for Perspective Therapeutics, Inc.'s products and services. As a biotechnology company developing radiopharmaceuticals for cancer treatment, the demand for its products is primarily driven by the ongoing medical need for cancer therapies, the progress and success of its clinical trials, regulatory approvals, and eventual market adoption, rather than typical seasonal consumer patterns.

Perspective Therapeutics, Inc. (CATX) is a clinical-stage radiopharmaceutical development company focused on pioneering advanced treatments for various cancers. The company operates within the Healthcare sector, specifically in the Biotechnology and Medical Devices industries. Perspective Therapeutics' core technology is its proprietary Targeted Alpha Therapy (TAT) platform, which utilizes the alpha-emitting isotope Lead-212 (Pb-212) to deliver potent radiation directly to cancer cells. Complementary to its therapeutic approach, the company also develops imaging diagnostics that incorporate the same targeting peptides, enabling a theranostic approach to personalize treatment and optimize patient outcomes. The company's major product candidates include VMT-α-NET (SSTR2), VMT01 (MC1R), and PSV359 (FAP-α).

Perspective Therapeutics, Inc. is headquartered in Seattle, Washington, United States. The company is expanding its U.S. manufacturing capabilities, including scaling up existing facilities and building out recently acquired sites, to support clinical trials and future commercial demands across major U.S. cancer centers. This includes a corporate asset purchase of a radiopharmaceutical manufacturing facility in Somerset, New Jersey, from Lantheus Holdings. The company's common stock is listed on the NYSE American (NYSEAM) in the US and also on the Deutsche Boerse AG (DB) in Germany.

Perspective Therapeutics has maintained a generally positive brand reputation over the past year, primarily driven by positive clinical trial data and favorable analyst coverage. The company has received an upgrade to a 'Buy' rating from analysts, with an average price target of $12.93. Analysts have initiated coverage with Overweight and Buy recommendations. Positive interim data from its lead cancer therapy trial has been a significant de-risking event. The acceptance of VMT-α-NET data for presentation at major scientific meetings further contributes to its scientific credibility and reputation. The company's commitment to advancing its clinical pipeline and expanding manufacturing capabilities also supports a positive image.

Perspective Therapeutics, Inc. has a mixed ownership structure comprising institutional investors, individual investors, and insiders. Approximately 23.28% to 54.66% of the company's stock is held by institutional investors. Insider ownership stands at around 1.66% to 3.72%. Public companies and individual investors hold a significant portion, estimated at 75.06% or 17.70%. Major institutional owners include BlackRock, Inc., Morgan Stanley, Vanguard Group Inc, Avidity Partners Management LP, Lantheus Holdings, Inc., TCG Crossover Management, LLC, Qatar Holding LLC, Commodore Capital Master LP, Nicholson Wealth Management Group, LLC, Geode Capital Management, Llc, Millennium Management Llc, Nuveen, LLC, Two Sigma Investments, Lp, Opaleye Management Inc., Sphera Funds Management LTD and Graham Capital Management, L.P.